South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US Food and Drug Administration (FDA) for its natural killer (NK) cell therapy candidate AB-101.
AB-101 is a cord blood-derived treatment aimed at harnessing the body's immune system to fight cancer. GC Cell transferred the technology for this product to Artiva.
The treatment is currently undergoing phase 1 and 2 clinical trials for patients with recurrent and intractable B-cell non-Hodgkin lymphoma, including those who have failed to respond to chimeric antigen receptor T cell (CAR-T) treatment.
The FDA's fast-track designation is given to drugs that show potential for excellent efficacy against life-threatening diseases and are in need of quick development.
GC Cell, which was created through the merger of GC Green Cross Lab Cell and GC Green Cross Cell, is a corporation focused on the development and production of treatments using immune cells and stem cells.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.